In this second of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.
In this first of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.
In this second part of a three-part video series, Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.
In this first part of a three-part video series, Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.
In this second part of a two-part video series, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.
In this part one video, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.
In this final part of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Summit Health’s Chief Quality Officer Ashish D. Parikh, MD, and Chief of Population Health Jamie Reedy, MD, about value-based care programs and contracts within Summit Health and what it takes to invest and implement these programs into your healthcare organization.
In this first part of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Summit Health’s Chief Quality Officer Ashish D. Parikh, MD, and Chief of Population Health Jamie Reedy, MD, about value-based care programs and contracts within Summit Health and what it takes to invest and implement these programs into your healthcare organization.
Debra Patt, MD, PhD, MBA, highlights how value-based care models affect treatment decisions for patients with HER2-positive metastatic breast cancer.
A key opinion leader describes treatment access considerations among patient with HER2-positive metastatic breast cancer.
Debra Patt, MD, PhD, MBA, explains how clinical practice has adapted to the use of targeted therapies to treat HER2-positive metastatic breast cancer.
Debra Patt, MD, PhD, MBA, discusses the cost considerations of conventional and novel therapies for HER2-positive metastatic breast cancer.
Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss unmet needs and future approaches to treatment in wet AMD.
Steven Peskin, MD, MBA, FACP, provides insight into managed care considerations of wet AMD including clinical evidence evaluation, formulary management, and value-based agreements.
Diana Do, MD, discusses outcomes of interest for anti-VEGF agents, clinical evidence supporting the treat-and-extend approach, and strategies to overcome financial barriers in wet AMD.
Diana Do, MD, provides insight into anti-VEGF treatment selection for individual patients, evaluation of patient response to therapy, and considerations for switching of agents.
Diana Do, MD, provides an overview of available anti-VEGF agents used in the treatment of wet AMD and Steven Peskin, MD, MBA, FACP, discusses management strategies employed with these agents.
Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss overtreatment and undertreatment in wet AMD in addition to the risks associated with delays in therapy.
Steven Peskin, MD, MBA, FACP, discusses drivers of cost and goals of therapy in wet AMD, and Diana Do, MD, discusses the different treatment approaches to the disease.
Diana Do, MD provides an overview of wet age-related macular degeneration including typical clinical manifestations, goals of therapy, and the current treatment landscape.
An expert in HER2-positive metastatic breast cancer discusses the new targeted treatment regimens for patients.
Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer.
The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.
The rationale for treating metastatic breast cancer with a dual HER2-targeted therapy approach.
In this part three video series, Civica Rx CEO Martin VanTrieste says Civica is launching an outpatient retail market with its first retail drug coming to the market next year.
Ian E Krop, MD, PhD, elaborates on which treatment settings are most appropriate to use HER2-targeted therapies in to manage metastatic breast cancer.
Considerations regarding how to best integrate newer targeted therapies available for HER2-positive metastatic breast cancer [MBC] into clinical practice.
Editors of MHE and their furry friends had the pleasure of speaking with Dr. Glenn Levine, professor of medicine at Baylor College of Medicine and chief of the cardiology section at Michael E. DeBakey VA Medical Center in Houston. Dr. Levine is also a volunteer medical expert for the American Heart Association’s Healthy Bond for Life initiative and is lead author of the Association’s Scientific Statement on Pet Ownership and Cardiovascular Risk. In the conversation, Dr. Levine shared some wellbeing tips on how our pets can benefit our mental and physical health and wellbeing.
Civica Rx CEO Martin VanTrieste says Civica’s members are experiencing fewer shortages because of strategies used by the company.
Ian E. Krop, MD, PhD, of Dana-Faber Cancer Institute, highlights more recent targeted therapy approvals for HER2-positive metastatic breast cancer and describes how each therapy is designed to work.
